Clinical Trials Browser

Phase 3 × Carcinoma, Non-Small-Cell Lung × Paclitaxel × Clear all

NCT04267848 2026-04-17

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06312137 2026-04-17

TroFuse-019

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03520686 2026-04-15

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT06623422 2026-04-14

INTerpath-009

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04092283 2026-04-13

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06422143 2026-04-02

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04205812 2026-03-31

POD1UM-304

Phase 3 Active not recruiting

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06692738 2026-03-31

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04379635 2026-03-18

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05984277 2026-03-17

eVOLVE-Lung02

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05687266 2026-03-13

AVANZAR

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03631199 2026-02-25

CANOPY-1

Phase 3 Terminated

673 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03774732 2026-02-25

NIRVANA-LUNG

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

712 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT07416474 2026-02-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05226598 2026-02-05

MK-7684A-007

Phase 3 Completed

739 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05502237 2026-01-30

STAR-121

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT06908993 2025-12-17

COMET

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06212752 2025-11-12

MK-3475A-D77

Phase 3 Active not recruiting

39 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Phase 3 Active not recruiting

461 enrolled 18 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT05722015 2025-09-11

MK-3475A-D77

Phase 3 Active not recruiting

377 enrolled 17 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04380636 2025-08-17

MK-7339-012

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00243867 2025-08-01

Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer

Phase 3 Completed

518 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT05298423 2025-08-01

KEYVIBE-006

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT07050043 2025-07-03

LEDANG

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05116462 2025-06-26

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03800134 2025-06-11

AEGEAN

Phase 3 Active not recruiting

825 enrolled 3 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03390686 2025-05-31

A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04585490 2025-05-06

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04564157 2025-04-10

NADIM-ADJUVANT

Phase 3 Active not recruiting

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02576574 2025-01-31

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Phase 3 Completed

1,214 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT01993810 2024-12-18

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02754882 2024-12-16

A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

Phase 3 Completed

763 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04956692 2024-12-03

MK-3475-A86

Phase 3 Active not recruiting

531 enrolled 18 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03594747 2024-10-26

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Phase 3 Completed

360 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT05487391 2024-10-15

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02775435 2024-10-08

KEYNOTE-407

Phase 3 Completed

559 enrolled 18 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03875092 2024-10-01

KEYNOTE-407

Phase 3 Completed

125 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05654454 2024-08-16

A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04194203 2024-07-19

A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT04158440 2024-07-09

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03117049 2024-05-06

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Phase 3 Completed

550 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03866993 2024-04-03

A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT01763645 2024-01-11

A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer

Phase 3 Completed

353 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung